GSK Sells Rights to Old IBS Drug Lotronex to Prometheus

GlaxoSmithKline has sold off the U.S. rights to its irritable bowel syndrome drug Lotronex to Prometheus Laboratories, which will continue to distribute the treatment through a restricted use programme across the Atlantic.
PharmaTimes